Stifle analysts cut their share price target for Inovio Pharmaceuticals Inc. INO, -6.08% to $ 16 from $ 24 on Tuesday, after the company posted a broader-than-expected second-quarter loss and revenue that fell short of estimate. Inovio is one of many companies working on developing a COVID-19 vaccine candidate. The …
Read More »Stifel cuts COVID-19 fax developer Inovio’s price target as revenue and calls more questions than answers
